Hims & Hers Health
HIMS
$28.15
-2.15%
Hims & Hers Health, Inc. is a telehealth platform that connects patients with healthcare providers for treatments in areas such as erectile dysfunction, hair loss, skin care, mental health, and weight loss, offering both prescription and over-the-counter products. As a direct-to-consumer digital health company, it has carved out a distinct niche by combining a user-friendly app with vertically integrated pharmacy and provider networks, amassing over 2 million subscribers. The current investor narrative centers on the company's aggressive expansion into the weight-loss drug market, highlighted by a recent partnership with Novo Nordisk, which has fueled revenue growth but also raised concerns about profitability and a debt-funded global expansion. The stock has been highly volatile, with a significant drawdown from its 52-week high, as investors weigh the potential of this high-growth market against rising costs and dilution risks.…
HIMS
Hims & Hers Health
$28.15
Related headlines
Investment Opinion: Should I buy HIMS Today?
Rating: Hold. The consensus analyst rating is 'Hold' with an average price target of $29.23, implying a negligible 1.5% downside from the current price. The thesis is that HIMS has significant growth potential in the weight-loss market, but near-term profitability challenges and high leverage warrant caution.
Sign up to view all
HIMS 12-Month Price Forecast
The AI assessment is neutral, reflecting the balanced risk-reward profile. While HIMS has a strong brand and a large subscriber base, the recent financial deterioration and high leverage create significant uncertainty. The stock's valuation is not compelling given the growth slowdown, but the Novo Nordisk partnership provides a potential catalyst. If the company can demonstrate a return to profitability and re-accelerate growth, the stance would upgrade to bullish. Conversely, if margins continue to compress and growth stalls, a bearish stance would be warranted.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Hims & Hers Health's 12-month outlook, with a consensus price target around $31.15 and implied upside of +10.7% versus the current price.
Average Target
$31.15
0 analysts
Implied Upside
+10.7%
vs. current price
Analyst Count
—
covering this stock
Price Range
$23 - $42
Analyst target range
Analyst coverage is moderate, with 13 analysts providing ratings, and the consensus recommendation is 'Hold' with a mean rating of 2.73 (where 1 is Strong Buy and 5 is Sell). The average price target is $29.23, which is essentially in line with the current price of $29.66, implying a negligible 1.5% downside. The distribution of ratings is not provided, but the 'Hold' consensus suggests a neutral stance, with analysts seeing limited upside at current levels. The target price range spans from a low of $21.00 to a high of $40.00, indicating a wide dispersion of views. The low target of $21.00 implies a 29% downside, likely reflecting concerns about continued margin compression and competitive pressures in the weight-loss market. The high target of $40.00 implies a 35% upside, which would require a successful execution of the Novo Nordisk partnership and a return to robust growth and profitability. Recent institutional actions show a mix of ratings, with B of A maintaining Neutral, while Canaccord Genuity and Needham reiterate Buy, and Barclays and JP Morgan hold Overweight, suggesting that while there is some bullish sentiment, the overall stance remains cautious. The wide target spread highlights the high uncertainty surrounding the company's future, particularly regarding its ability to navigate the competitive and regulatory landscape in the weight-loss drug market.
Bulls vs Bears: HIMS Investment Factors
Hims & Hers is at a critical juncture, with the bull case hinging on the successful execution of its weight-loss drug strategy and the Novo Nordisk partnership, while the bear case is driven by deteriorating profitability, slowing growth, and high leverage. Currently, the bearish evidence is stronger, as the company's recent financials show a clear deterioration in margins and a swing to losses, while the stock trades at a premium valuation. The most important tension is whether the weight-loss drug expansion can re-accelerate growth and restore profitability, or if it will continue to erode margins and lead to further dilution. If the company can demonstrate a path to profitability in the weight-loss segment, the stock could re-rate higher; otherwise, it faces significant downside risk.
Bullish
- Strong Revenue Growth Potential: Despite a recent slowdown, HIMS has demonstrated robust revenue growth historically, with Q1 2025 revenue up 21.6% YoY. The partnership with Novo Nordisk to offer weight-loss drugs positions the company in a high-growth market, potentially re-accelerating growth.
- Large Subscriber Base: With over 2 million subscribers, HIMS has a substantial and loyal customer base. This provides a solid foundation for cross-selling new services like weight-loss treatments, which could drive incremental revenue without proportional increases in marketing spend.
- Strategic Partnership with Novo Nordisk: The Novo Nordisk partnership, announced in March 2026, removes a major legal overhang and provides a credible supply of weight-loss drugs. This could significantly expand HIMS's total addressable market and drive long-term growth.
- High Gross Margin Potential: Historically, HIMS has maintained gross margins above 70%, with Q1 2025 at 73.5%. While Q1 2026 saw a dip to 49.4% due to the weight-loss drug mix, the underlying business model has proven scalable and profitable at scale.
Bearish
- Sharp Revenue Growth Deceleration: Q1 2026 revenue growth was only 3.77% YoY, a dramatic slowdown from 21.6% in Q1 2025. This deceleration raises concerns about the company's ability to sustain growth, especially as it pivots to weight-loss drugs.
- Deteriorating Profitability: HIMS swung to a net loss of $92.1 million in Q1 2026, compared to a net income of $49.5 million in the year-ago quarter. The net margin turned deeply negative at -15.1%, indicating that the weight-loss drug expansion is currently unprofitable.
- High Debt and Dilution Risk: The debt-to-equity ratio stands at 2.07, reflecting substantial leverage. A recent $350 million convertible debt offering threatens significant shareholder dilution, which could pressure the stock price further.
- Gross Margin Compression: Gross margin fell to 49.4% in Q1 2026 from 73.5% a year earlier, a 24.1 percentage point decline. This reflects the higher cost structure of weight-loss drugs and increased competition, which could persist.
HIMS Technical Analysis
Hims & Hers is in a pronounced downtrend over the past year, with the stock down 41.99% over the last 12 months, significantly underperforming the S&P 500's 21.46% gain. The current price of $29.66 sits at approximately 45.4% of its 52-week range (between $13.74 low and $65.30 high), indicating the stock is closer to its lows than its highs. This positioning suggests that while the stock has recovered from its absolute bottom, it remains in a bearish structure, with the 52-week high representing a distant resistance level that would require a substantial rally to reclaim.
Beta
2.42
2.42x market volatility
Max Drawdown
-78.1%
Largest decline past year
52-Week Range
$14-$65
Price range past year
Annual Return
-40.3%
Cumulative gain past year
| Period | HIMS Return | S&P 500 |
|---|---|---|
| 1m | -24.3% | +2.9% |
| 3m | +12.4% | +5.0% |
| 6m | +72.7% | +13.9% |
| 1y | -40.3% | +20.4% |
| ytd | -15.7% | +13.8% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
HIMS Fundamental Analysis
Revenue growth has decelerated sharply, with the most recent quarter (Q1 2026) showing revenue of $608.1 million, a mere 3.77% year-over-year increase, a dramatic slowdown from the 21.6% growth seen in Q1 2025. This deceleration is concerning, especially as the company's pivot to weight-loss drugs was expected to drive acceleration. The company swung to a net loss of $92.1 million in Q1 2026, compared to a net income of $49.5 million in the year-ago quarter, with a net margin of -15.1%. Gross margin also compressed significantly to 49.4% from 73.5% a year earlier, reflecting the higher cost structure of the weight-loss drug business and increased competition. The company's balance sheet shows a debt-to-equity ratio of 2.07, indicating substantial leverage, and while it generated $89.4 million in operating cash flow in Q1 2026, free cash flow was only $53.0 million due to heavy capital expenditures. The return on equity is 23.7%, but this is distorted by the recent loss; the current ratio of 1.90 suggests adequate liquidity, but the rising debt levels and negative net income raise concerns about financial sustainability.
Quarterly Revenue
$608104000.0B
2026-03
Revenue YoY Growth
+3.8%
YoY Comparison
Gross Margin
49.4%
Latest Quarter
Free Cash Flow
$75838000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Open an Account, get $2 TSLA now!
Valuation Analysis: Is HIMS Overvalued?
Given the negative trailing net income, the price-to-sales (PS) ratio is the most appropriate valuation metric, and at 3.11x, it reflects the market's continued premium for the company's growth potential. The forward PE of 22.73x implies that analysts expect a significant earnings recovery, but the negative PEG ratio of -33.04 suggests that growth is not expected to justify the current valuation. Compared to the industry average PS ratio of 3.11x (from the data), HIMS trades at a 0% premium, indicating it is fairly valued relative to peers on a sales basis. However, this comparison is misleading given the company's recent profitability issues; its gross margin of 73.8% is above the industry average, but its operating margin of 4.5% is below, reflecting high operating expenses. Historically, the stock's PS ratio has ranged from 5.8x to 34.4x over the past five years, and the current 3.11x is near the bottom of that range, suggesting the market is pricing in significant pessimism or a structural decline in growth.
PE
57.0x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 13x~90x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
45.9x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: HIMS faces significant financial risks, including a high debt-to-equity ratio of 2.07, which indicates substantial leverage that could strain cash flows. The company swung to a net loss of $92.1 million in Q1 2026, with a net margin of -15.1%, reflecting the high costs of its weight-loss drug expansion. Free cash flow was only $53.0 million in Q1 2026, down from operating cash flow of $89.4 million, due to heavy capital expenditures, which may not be sustainable. Additionally, revenue growth decelerated sharply to 3.77% YoY, raising concerns about the company's ability to generate sufficient returns on its investments.